Magnetic resonance imaging-based radiomics was used to evaluate the level of prognosis-related immune cell infiltration in breast cancer tumor microenvironment

Table 1 Clinical and pathological Characteristics for 73 Patients

	Tumor with high M2 Macrophages infiltrate (n = 36,49.3%)	Tumor with low M2 Macrophages infiltrate (n = 37,50.7%)	p value^a
Age
Median	59	53
Mean ± SD	58.0 ± 12.0	52.7 ± 11.2
T			0.710
T1	15(45.5)	18(54.5)
T2	19(54.3)	16(45.7)
T3	2(40.0)	3(60.0)
N			0.466
N0	17 (50.0)	17 (50.0)
N1	14(48.3)	15(51.7)
N2	1(20.0)	4(80.0)
N3	3(75.0)	1(25.0)
Nx^b	1(100.0)	0(0)
M			0.457
M0	23(46.0)	27(54.0)
Mx^c	13(56.5)	10(43.5)
Stage
I	9(47.4)	10(52.6)	0.843
II	23(52.3)	21(47.7)
III	4(40.0)	6(60.0)
Histological Type			1.000
Invasive Ductal Carcinoma	31(49.2)	32(50.8)
Invasive Lobular Carcinoma	4(50.0)	4(50.0)
Other	1(50.0)	1(50.0)
ER			0.189
Positive	33(54.1)	29(45.9)
Negative	3(27.3)	8(72.7)
PR			0.794
Positive	27(50.9)	26(49.1)
Negative	9(45.0)	11(55.0)
HER2			0.646
Positive	7(58.3)	5(41.7)
Negative	29(48.3)	31(51.7)
Equivocal	0(0)	1(100.0)
IHC type			0.288
HR+/HER2-	26(52.0)	24(48.0)
HER2+	7(58.3)	5(41.7)
ER−/PR−/HER2-	3(27.3)	8(72.7)

Abbreviations: T the primary tumor, N regional lymph nodes, and M distant metastases, ER Estrogen receptor, HER2 Human epidermal growth factor receptor 2, HR Hormone receptor, PR Progesterone receptor, a Fisher’s exact test, b Lymph node stage is not available, c Metastasis cannot be measured

ISSN: 1471-2342